South Korea · Delayed Price · Currency is KRW SLS BIO Statistics
Total Valuation
SLS BIO has a market cap or net worth of KRW 26.89 billion. The enterprise value is 20.82 billion.
| Market Cap | 26.89B |
| Enterprise Value | 20.82B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SLS BIO has 13.66 million shares outstanding. The number of shares has decreased by -11.76% in one year.
| Current Share Class | 13.66M |
| Shares Outstanding | 13.66M |
| Shares Change (YoY) | -11.76% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 34.28% |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.31 |
| PB Ratio | 4.65 |
| P/TBV Ratio | 4.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.38 |
| Quick Ratio | 1.29 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.30 |
| Interest Coverage | -80.52 |
Financial Efficiency
Return on equity (ROE) is -64.25% and return on invested capital (ROIC) is -86.29%.
| Return on Equity (ROE) | -64.25% |
| Return on Assets (ROA) | -26.16% |
| Return on Invested Capital (ROIC) | -86.29% |
| Return on Capital Employed (ROCE) | -69.18% |
| Weighted Average Cost of Capital (WACC) | 6.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.24 |
| Inventory Turnover | 31.62 |
Taxes
| Income Tax | -866.50M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.58% in the last 52 weeks. The beta is 0.51, so SLS BIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -15.58% |
| 50-Day Moving Average | 1,829.32 |
| 200-Day Moving Average | 2,434.91 |
| Relative Strength Index (RSI) | 48.32 |
| Average Volume (20 Days) | 4,356,170 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SLS BIO had revenue of KRW 2.89 billion and -5.43 billion in losses. Loss per share was -361.07.
| Revenue | 2.89B |
| Gross Profit | -2.57B |
| Operating Income | -5.06B |
| Pretax Income | -6.29B |
| Net Income | -5.43B |
| EBITDA | -3.80B |
| EBIT | -5.06B |
| Loss Per Share | -361.07 |
Balance Sheet
The company has 1.84 billion in cash and 1.44 billion in debt, with a net cash position of 399.16 million or 29.23 per share.
| Cash & Cash Equivalents | 1.84B |
| Total Debt | 1.44B |
| Net Cash | 399.16M |
| Net Cash Per Share | 29.23 |
| Equity (Book Value) | 5.78B |
| Book Value Per Share | 391.98 |
| Working Capital | 916.03M |
Cash Flow
In the last 12 months, operating cash flow was -3.70 billion and capital expenditures -1.11 billion, giving a free cash flow of -4.81 billion.
| Operating Cash Flow | -3.70B |
| Capital Expenditures | -1.11B |
| Depreciation & Amortization | 1.27B |
| Net Borrowing | -622.27M |
| Free Cash Flow | -4.81B |
| FCF Per Share | -352.15 |
Margins
Gross margin is -88.99%, with operating and profit margins of -175.14% and -187.87%.
| Gross Margin | -88.99% |
| Operating Margin | -175.14% |
| Pretax Margin | -217.86% |
| Profit Margin | -187.87% |
| EBITDA Margin | -131.67% |
| EBIT Margin | -175.14% |
| FCF Margin | n/a |
Dividends & Yields
SLS BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 11.76% |
| Shareholder Yield | 11.76% |
| Earnings Yield | -20.19% |
| FCF Yield | -17.88% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 12, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Jul 12, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
SLS BIO has an Altman Z-Score of -1.68 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.68 |
| Piotroski F-Score | 1 |